SI2540728T1 - Heterociklična spojina - Google Patents

Heterociklična spojina

Info

Publication number: SI2540728T1
Authority: SI; Slovenia
Prior art keywords: heterocyclic compound; heterocyclic; compound
Prior art date: 2010-02-17

Application number

SI201131722T

Other languages

English (en)

Inventor

Misaki Homma

Toru Miyazaki

Yuya Oguro

Osamu Kurasawa

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-17

Filing date

2011-02-16

Publication date

2019-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2540728(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-02-16 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2019-06-28 Publication of SI2540728T1 publication Critical patent/SI2540728T1/sl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems

SI201131722T 2010-02-17 2011-02-16 Heterociklična spojina SI2540728T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2010031899		2010-02-17
JP2010131950		2010-06-09
EP11744685.6A EP2540728B1 (en)	2010-02-17	2011-02-16	Heterocyclic compound
PCT/JP2011/053303 WO2011102399A1 (ja)	2010-02-17	2011-02-16	複素環化合物

Publications (1)

Publication Number	Publication Date
SI2540728T1 true SI2540728T1 (sl)	2019-06-28

Family

ID=44482985

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201131722T SI2540728T1 (sl)	2010-02-17	2011-02-16	Heterociklična spojina

Country Status (35)

Country	Link
US (6)	US8722660B2 (sl)
EP (2)	EP3533797B1 (sl)
JP (1)	JP5689454B2 (sl)
KR (1)	KR101735868B1 (sl)
CN (1)	CN102844320B (sl)
AU (1)	AU2011216404B2 (sl)
BR (1)	BR112012020311B1 (sl)
CA (1)	CA2790284C (sl)
CL (1)	CL2012002250A1 (sl)
CO (1)	CO6592104A2 (sl)
CR (1)	CR20120448A (sl)
CY (1)	CY1121792T1 (sl)
DK (1)	DK2540728T3 (sl)
DO (1)	DOP2012000224A (sl)
EA (1)	EA020724B1 (sl)
EC (1)	ECSP12012160A (sl)
ES (1)	ES2733221T3 (sl)
GE (1)	GEP20146202B (sl)
HR (1)	HRP20190947T1 (sl)
HU (1)	HUE043514T2 (sl)
IL (1)	IL221442A0 (sl)
LT (1)	LT2540728T (sl)
MA (1)	MA34064B1 (sl)
ME (1)	ME03410B (sl)
MX (1)	MX353500B (sl)
MY (1)	MY164776A (sl)
NZ (1)	NZ602089A (sl)
PE (1)	PE20130184A1 (sl)
PL (1)	PL2540728T3 (sl)
PT (1)	PT2540728T (sl)
RS (1)	RS58796B1 (sl)
SG (1)	SG183304A1 (sl)
SI (1)	SI2540728T1 (sl)
TN (1)	TN2012000401A1 (sl)
WO (1)	WO2011102399A1 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA34797B1 (fr) *	2010-08-11	2014-01-02	Millennium Pharm Inc	Hétéroaryles et leurs utilisations
EP3100742B1 (en)	2014-01-31	2020-05-20	Carna Biosciences Inc.	Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
TW201620879A (zh)	2014-04-28	2016-06-16	杜邦股份有限公司	除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) *	2014-05-05	2019-01-08	Signalrx Pharmaceuticals, Inc.	Heterocyclic compound classes for signaling modulation
KR20190090081A (ko)	2015-12-07	2019-07-31	지머젠 인코포레이티드	Htp 게놈 공학 플랫폼에 의한 미생물 균주 개량
SG11201804901WA (en)	2015-12-22	2018-07-30	SHY Therapeutics LLC	Compounds for the treatment of cancer and inflammatory disease
WO2017172565A1 (en)	2016-03-28	2017-10-05	Takeda Pharmaceutical Company Limited	Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate
EA035560B1 (ru) *	2016-07-28	2020-07-07	Такеда Фармасьютикал Компани Лимитед	Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
AU2017359561B2 (en)	2016-11-08	2022-02-03	Cancer Research Technology Limited	Pyrimidinone derivatives as Cdc7 inhibitors
WO2018158898A1 (en)	2017-03-01	2018-09-07	Takeda Pharmaceutical Company Limited	Method of predicting effects of cdc7 inhibitor
WO2018217439A1 (en) *	2017-05-21	2018-11-29	Zhang Hai Jun	Substituted [5,6]cyclic-4(3h)-pyrimidinones as anticancer agents
EA201992780A1 (ru)	2017-06-21	2020-06-02	ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи	Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2019194319A1 (en)	2018-04-02	2019-10-10	Takeda Pharmaceutical Company Limited	Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
TW202016316A (zh)	2018-06-19	2020-05-01	日商武田藥品工業股份有限公司	癌症治療方法
US20210308061A1 (en)	2018-07-19	2021-10-07	Taked Pharmaceutical Company Limited	Pharmaceutical compositions with a cdc7 inhibitor
CA3142202A1 (en) *	2019-05-30	2020-12-03	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Tetracyclic compounds as cdc7 inhibitors
WO2021015294A2 (en)	2019-07-19	2021-01-28	Takeda Pharmaceutical Company Limited	Combination therapy for cancer treatment
WO2021032170A1 (zh) *	2019-08-20	2021-02-25	南京明德新药研发有限公司	用作Cdc7抑制剂的四并环类化合物
EP4069369A4 (en) *	2019-12-06	2024-02-14	Schroedinger Inc	CYCLIC COMPOUNDS AND METHODS OF USE THEREOF
WO2022055963A1 (en) *	2020-09-10	2022-03-17	Schrödinger, Inc.	Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
CN116472046A (zh) *	2020-11-30	2023-07-21	正大天晴药业集团股份有限公司	作为Cdc7抑制剂的盐型及其晶型
CN112661770B (zh) *	2020-12-24	2022-11-08	南京正济医药研究有限公司	一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
WO2022167999A1 (en)	2021-02-08	2022-08-11	Takeda Pharmaceutical Company Limited	Combination therapy for cancer treatment
TW202300150A (zh) *	2021-03-18	2023-01-01	美商薛定諤公司	環狀化合物及其使用方法
TW202330552A (zh) *	2021-10-13	2023-08-01	美商雷密克斯醫療公司	調節剪接之化合物及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196207A (en) *	1977-05-23	1980-04-01	Ici Australia Limited	Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE19644228A1 (de) *	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
AUPO721997A0 (en)	1997-06-06	1997-07-03	Queensland Institute Of Medical Research, The	Anticancer compounds
JP2002105081A (ja)	2000-07-28	2002-04-10	Nikken Chem Co Ltd	新規チオフェンニ環化合物
AU2001290311A1 (en)	2000-09-29	2002-04-08	Nippon Soda Co., Ltd.	Thienopyrimidine compounds and their salts and process for preparation of both
US6503914B1 (en)	2000-10-23	2003-01-07	Board Of Regents, The University Of Texas System	Thienopyrimidine-based inhibitors of the Src family
US20030096813A1 (en)	2001-04-20	2003-05-22	Jingrong Cao	Compositions useful as inhibitors of GSK-3
AU2003246972A1 (en)	2002-08-06	2004-02-23	Astrazeneca Ab	Condensed pyridines and pyrimidines with tie2 (tek) activity
WO2004111014A1 (en)	2003-06-06	2004-12-23	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
MXPA05013549A (es) *	2003-06-11	2006-04-05	Xention Discovery Ltd	Derivados de tienopirimidina como inhibidores del canal de potasio.
US20050032869A1 (en)	2003-07-08	2005-02-10	Pharmacia Italia S.P.A.	Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BRPI0413438A (pt) *	2003-08-08	2006-10-17	Pharmacia Italia Spa	derivados de pirimidilpirrol ativos como inibidores de cinase
US7279575B2 (en)	2003-08-08	2007-10-09	Pfizer Italia S.R.L.	Pyrimidylpyrrole derivatives active as kinase inhibitors
BRPI0508230A (pt) *	2004-03-30	2007-07-17	Chiron Corp	derivados de tiofeno substituìdo como agentes anti-cáncer
EP1757306A4 (en)	2004-04-09	2010-05-19	Genecare Res Inst Co Ltd	AGENT INDUCING APOPTOSIS SPECIFIC TO CARCINOMA CELLS TARGETING A GENE INVOLVED IN STABILIZING CHROMOSOMES
US20080102068A1 (en)	2005-01-19	2008-05-01	Coleman Paul J	Mitotic Kinesin Inhibitors
WO2007011284A1 (en)	2005-07-15	2007-01-25	Astrazeneca Ab	Therapeutic agents
CN101253166B (zh)	2005-08-30	2013-07-10	旭化成制药株式会社	磺酰胺化合物
FI20055498A0 (fi)	2005-09-16	2005-09-16	Biotie Therapies Corp	Sulfonamidijohdannaisia
US20070142414A1 (en) *	2005-12-16	2007-06-21	Pharmacia Italia S.P.A.	N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) *	2005-12-19	2009-11-17	Nerviano Medical Sciences S.R.L.	Heteroarylpyrrolopyridinones active as kinase inhibitors
KR100846988B1 (ko)	2006-03-06	2008-07-16	제일약품주식회사	신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
US20090030196A1 (en)	2006-12-29	2009-01-29	Abbott Laboratories	Pim kinase inhibitors as cancer chemotherapeutics
WO2008082839A2 (en)	2006-12-29	2008-07-10	Abbott Laboratories	Pim kinase inhibitors as cancer chemotherapeutics
TW200836743A (en)	2007-01-29	2008-09-16	Xenon Pharmaceuticals Inc	Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2009001214A2 (en)	2007-06-28	2008-12-31	Pfizer Products Inc.	Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en)	2007-11-02	2009-05-07	Wyeth	Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en)	2008-03-11	2011-04-28	Jeremy Major	Sulfonamides as zap-70 inhibitors
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
AU2009262022A1 (en)	2008-06-26	2009-12-30	Dana-Farber Cancer Institute, Inc.	Signatures and determinants associated with metastasis and methods of use thereof
US8691828B2 (en)	2009-03-05	2014-04-08	Takeda Pharmaceutical Company Limited	Thienopyrimidine as CDC7 kinase inhibitors
WO2010126002A1 (ja)	2009-04-28	2010-11-04	塩野義製薬株式会社	ヘテロ環スルホンアミド化合物を含有する医薬
TW201111378A (en)	2009-09-11	2011-04-01	Bayer Schering Pharma Ag	Substituted (heteroarylmethyl) thiohydantoins
CA2773615A1 (en)	2009-09-11	2011-03-17	Arwed Cleve	Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
AR079343A1 (es)	2009-12-21	2012-01-18	Lilly Co Eli	Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

2011
- 2011-02-16 EP EP19168244.2A patent/EP3533797B1/en active Active
- 2011-02-16 NZ NZ602089A patent/NZ602089A/en unknown
- 2011-02-16 ME MEP-2019-152A patent/ME03410B/me unknown
- 2011-02-16 MA MA35205A patent/MA34064B1/fr unknown
- 2011-02-16 SI SI201131722T patent/SI2540728T1/sl unknown
- 2011-02-16 KR KR1020127024086A patent/KR101735868B1/ko active IP Right Grant
- 2011-02-16 JP JP2012500632A patent/JP5689454B2/ja active Active
- 2011-02-16 CA CA2790284A patent/CA2790284C/en active Active
- 2011-02-16 PL PL11744685T patent/PL2540728T3/pl unknown
- 2011-02-16 WO PCT/JP2011/053303 patent/WO2011102399A1/ja active Application Filing
- 2011-02-16 EP EP11744685.6A patent/EP2540728B1/en active Active
- 2011-02-16 LT LTEP11744685.6T patent/LT2540728T/lt unknown
- 2011-02-16 GE GEAP201112855A patent/GEP20146202B/en unknown
- 2011-02-16 ES ES11744685T patent/ES2733221T3/es active Active
- 2011-02-16 BR BR112012020311-8A patent/BR112012020311B1/pt active IP Right Grant
- 2011-02-16 MX MX2012009602A patent/MX353500B/es active IP Right Grant
- 2011-02-16 AU AU2011216404A patent/AU2011216404B2/en active Active
- 2011-02-16 MY MYPI2012003715A patent/MY164776A/en unknown
- 2011-02-16 CN CN201180019478.3A patent/CN102844320B/zh active Active
- 2011-02-16 PT PT11744685T patent/PT2540728T/pt unknown
- 2011-02-16 DK DK11744685.6T patent/DK2540728T3/da active
- 2011-02-16 RS RS20190639A patent/RS58796B1/sr unknown
- 2011-02-16 EA EA201290800A patent/EA020724B1/ru unknown
- 2011-02-16 SG SG2012059994A patent/SG183304A1/en unknown
- 2011-02-16 PE PE2012001253A patent/PE20130184A1/es active IP Right Grant
- 2011-02-16 US US13/578,959 patent/US8722660B2/en active Active
- 2011-02-16 HU HUE11744685A patent/HUE043514T2/hu unknown
2012
- 2012-08-09 TN TNP2012000401A patent/TN2012000401A1/en unknown
- 2012-08-14 CL CL2012002250A patent/CL2012002250A1/es unknown
- 2012-08-14 IL IL221442A patent/IL221442A0/en active IP Right Grant
- 2012-08-15 DO DO2012000224A patent/DOP2012000224A/es unknown
- 2012-08-29 CR CR20120448A patent/CR20120448A/es unknown
- 2012-09-13 CO CO12158066A patent/CO6592104A2/es active IP Right Grant
- 2012-09-17 EC ECSP12012160 patent/ECSP12012160A/es unknown
2014
- 2014-03-24 US US14/223,259 patent/US8921354B2/en active Active
- 2014-03-24 US US14/223,329 patent/US8933069B2/en active Active
- 2014-12-10 US US14/566,157 patent/US9388195B2/en active Active
2016
- 2016-06-08 US US15/176,893 patent/US9655900B2/en active Active
2017
- 2017-04-11 US US15/484,755 patent/US20170209452A1/en not_active Abandoned
2019
- 2019-05-23 HR HRP20190947TT patent/HRP20190947T1/hr unknown
- 2019-07-09 CY CY20191100721T patent/CY1121792T1/el unknown

Also Published As

Publication number	Publication date
TN2012000401A1 (en)	2014-01-30
PT2540728T (pt)	2019-07-11
CA2790284C (en)	2019-01-08
US20170209452A1 (en)	2017-07-27
ECSP12012160A (es)	2013-03-28
DOP2012000224A (es)	2013-01-31
BR112012020311B1 (pt)	2019-01-29
US9655900B2 (en)	2017-05-23
US20160310494A1 (en)	2016-10-27
SG183304A1 (en)	2012-09-27
US20140235615A1 (en)	2014-08-21
EP3533797B1 (en)	2023-12-20
JP5689454B2 (ja)	2015-03-25
MX2012009602A (es)	2012-12-17
US20150158882A1 (en)	2015-06-11
AU2011216404B2 (en)	2016-04-07
HUE043514T2 (hu)	2019-08-28
US8933069B2 (en)	2015-01-13
RS58796B1 (sr)	2019-07-31
BR112012020311A2 (pt)	2017-03-01
MY164776A (en)	2018-01-30
EP2540728A1 (en)	2013-01-02
CR20120448A (es)	2012-11-13
CY1121792T1 (el)	2020-07-31
PL2540728T3 (pl)	2019-09-30
US20130029969A1 (en)	2013-01-31
HRP20190947T1 (hr)	2019-07-26
KR101735868B1 (ko)	2017-05-15
CN102844320A (zh)	2012-12-26
IL221442A0 (en)	2012-10-31
MA34064B1 (fr)	2013-03-05
MX353500B (es)	2018-01-16
CA2790284A1 (en)	2011-08-25
WO2011102399A1 (ja)	2011-08-25
EP2540728A4 (en)	2013-11-06
GEP20146202B (en)	2014-11-25
EA020724B1 (ru)	2015-01-30
DK2540728T3 (da)	2019-05-13
CL2012002250A1 (es)	2013-02-08
PE20130184A1 (es)	2013-03-09
AU2011216404A1 (en)	2012-09-20
JPWO2011102399A1 (ja)	2013-06-17
CO6592104A2 (es)	2013-01-02
EP3533797A1 (en)	2019-09-04
ES2733221T3 (es)	2019-11-28
EA201290800A1 (ru)	2013-03-29
LT2540728T (lt)	2019-06-25
KR20130001246A (ko)	2013-01-03
EP2540728B1 (en)	2019-04-10
ME03410B (me)	2020-01-20
US8722660B2 (en)	2014-05-13
US9388195B2 (en)	2016-07-12
CN102844320B (zh)	2016-03-23
US8921354B2 (en)	2014-12-30
NZ602089A (en)	2014-05-30
US20140228352A1 (en)	2014-08-14

Publication	Publication Date	Title
HRP20181788T1 (hr)	2018-12-28	Supstituirani spojevi piridinon-piridinil
IL221442A0 (en)	2012-10-31	Heterocyclic compound
IL225770A0 (en)	2013-06-27	Heterocyclic compounds
ZA201300950B (en)	2014-04-30	Heterocyclic compound
EP2738170A4 (en)	2014-12-31	HETEROCYCLIC COMPOUND
PL2521450T3 (pl)	2015-07-31	Grzybobójcze związki heterocykliczne
EP2590647A4 (en)	2014-05-21	PRO-NEUROGENIC COMPOUNDS
GB201008134D0 (en)	2010-06-30	Compounds
GB201007347D0 (en)	2010-06-16	Compounds
EP2709609A4 (en)	2015-08-26	HETEROCYCLIC COMPOUNDS
EP2605658A4 (en)	2014-05-07	SPIROXAZOLIDINONVERBINDUNGEN
EP2649050A4 (en)	2014-04-23	LINKS
GB201002563D0 (en)	2010-03-31	Compounds
EP2583965A4 (en)	2013-09-18	HETEROCYCLIC RING CONNECTION
GB201001688D0 (en)	2010-03-17	Compounds
GB201002911D0 (en)	2010-04-07	Compound
GB201017315D0 (en)	2010-11-24	Compound
GB201007789D0 (en)	2010-06-23	Novel Compound
GB201002216D0 (en)	2010-03-31	Compounds
GB201001796D0 (en)	2010-03-24	Compounds
GB201007209D0 (en)	2010-06-16	Compound
EP2527343A4 (en)	2013-08-14	HETEROCYCLIC CONNECTION WITH AN AOLA GROUP
GB201021416D0 (en)	2011-01-26	Novel heterocyclic compounds
GB201009514D0 (en)	2010-07-21	Novel heterocyclic compounds
GB201021228D0 (en)	2011-01-26	Compound